Odalasvir
Odalasvir (INN, previously known as ACH-3102) is an investigational new drug in development for the treatment of hepatitis C. It is an NS5A inhibitor. The NS5A protein serves multiple functions at various stages of the viral life cycle, including viral replication. NS5A also plays a role in the development of interferon-resistance, a common cause of treatment failure. It is under development by .
Wikipage redirect
Link from a Wikipage to another Wikipage
primaryTopic
Odalasvir
Odalasvir (INN, previously known as ACH-3102) is an investigational new drug in development for the treatment of hepatitis C. It is an NS5A inhibitor. The NS5A protein serves multiple functions at various stages of the viral life cycle, including viral replication. NS5A also plays a role in the development of interferon-resistance, a common cause of treatment failure. It is under development by .
has abstract
Odalasvir (INN, previously kno ...... . It is under development by .
@en
CAS number
1415119-52-6
FDA UNII code
OVR52K7BDW
PubChem
Wikipage page ID
45,661,541
page length (characters) of wiki page
Wikipage revision ID
1,001,465,585
Link from a Wikipage to another Wikipage
CAS number
ChemSpiderID
34,500,837
IUPAC name
Dimethyl N,N'-biscarbamate
@en
legal US
Investigational New Drug
@en
PubChem
71,474,517
SMILES
CC[C@@H]NCOC
@en
StdInChIKey
LSYBRGMTRKJATA-IVEWBXRVSA-N
@en
UNII
OVR52K7BDW
@en
wikiPageUsesTemplate
hypernym
comment
Odalasvir (INN, previously kno ...... . It is under development by .
@en
label
Odalasvir
@en